Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Black Diamond Therapeutics Inc (BDTX)

$1.86 +0.25 (15.53%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	92.26M
Revenue (ttm)	70.00M
Net Income (ttm)	22.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	31.96%
Debt to Equity Ratio	0.00

Volume	2,870,400
Avg Vol	1,586,794
Day's Range	N/A - N/A
Shares Out	57.30M
Stochastic %K	3%
Beta	3.22
Analysts	Strong Sell
Price Target	$9.86

Company Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also dev...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 252 0848

Website: www.blackdiamondtherapeutics.com

Address:

245 First Street, 18th Floor, Cambridge, United States

topstockalerts Jun. 25 at 1:29 AM

$BDTX the stock keeps earning a closer look.

0 · Reply

StockScanners Jun. 25 at 1:03 AM

$BDTX keep watch if this holds above 1.80

0 · Reply

Kinghargis Jun. 24 at 11:00 PM

$BDTX some whale just bought a

0 · Reply

Kinghargis Jun. 24 at 8:10 PM

$BDTX 2 dollar calls smell

0 · Reply

topstockalerts Jun. 24 at 8:07 PM

$BDTX the strength here is subtle but persistent.

0 · Reply

Theflash88 Jun. 24 at 7:10 PM

$BDTX Yes

0 · Reply

Kinghargis Jun. 24 at 6:30 PM

$BDTX heard theres news brewing

1 · Reply

BossTrade Jun. 24 at 6:28 PM

$BDTX Usually a run up like this means something about to go down

0 · Reply

kubertradespennies Jun. 24 at 6:15 PM

$BDTX heard the news yet?

0 · Reply

BossTrade Jun. 24 at 5:36 PM

$BDTX I anticipate mild plateau and consolidation before gap up

0 · Reply

Black Diamond Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 22, 2026, 8:00 AM EDT - 4 weeks ago

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 21, 2026, 5:30 PM EDT - 4 weeks ago

Black Diamond Therapeutics Transcript: Study result

May 21, 2026, 5:30 PM EDT - 4 weeks ago

Black Diamond Therapeutics Press release: Study result

May 21, 2026, 5:13 PM EDT - 4 weeks ago

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

May 21, 2026, 7:00 AM EDT - 4 weeks ago

Black Diamond Therapeutics Slides: Corporate presentation

May 19, 2026, 8:00 AM EDT - 5 weeks ago

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

May 7, 2026, 7:30 AM EDT - 6 weeks ago

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Black Diamond Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 6 weeks ago

Black Diamond Therapeutics Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Black Diamond Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Black Diamond Therapeutics Proxy statement: Proxy filing

2026-04-29T10:21:57.000Z - 2 months ago

Black Diamond price target raised to $11 from $10 at H.C. Wainwright

Apr 21, 2026, 10:40 AM EDT - 2 months ago

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

2026-03-17T11:51:25.000Z - 3 months ago

Black Diamond Therapeutics price target raised to $14 from $13 at Wedbush

2026-03-16T20:05:26.000Z - 3 months ago

Black Diamond Therapeutics reports Q4 EPS (27c), consensus (17c)

Mar 16, 2026, 4:01 PM EDT - 3 months ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 16, 2026, 7:00 AM EDT - 3 months ago

Black Diamond Therapeutics Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 3 months ago

Black Diamond Therapeutics Annual report: Q4 2025

Mar 4, 2026, 1:10 PM EST - 4 months ago

Black Diamond Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 4:01 PM EST - 4 months ago

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

2026-01-16T11:55:20.000Z - 5 months ago

Black Diamond Therapeutics price target lowered to $8 from $9 at Piper Sandler

Dec 4, 2025, 1:00 PM EST - 7 months ago

Black Diamond Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-03T17:40:19.000Z - 7 months ago

Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim

2025-12-03T17:35:12.000Z - 7 months ago

Black Diamond Therapeutics downgraded to Neutral from Buy at Guggenheim

Dec 3, 2025, 8:00 AM EST - 7 months ago

Black Diamond Therapeutics Transcript: Study Update

Dec 3, 2025, 8:00 AM EST - 7 months ago

Black Diamond Therapeutics Press release: Study Update

2025-12-03T12:11:22.000Z - 7 months ago

Black Diamond Therapeutics announces data from Phase 2 trial of silevertinib

Dec 3, 2025, 7:01 AM EST - 7 months ago

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Dec 2, 2025, 4:01 PM EST - 7 months ago

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

2025-11-17T21:50:17.000Z - 7 months ago

Black Diamond Therapeutics assumed with an Overweight at Piper Sandler

2025-11-13T22:25:31.000Z - 7 months ago

Black Diamond Therapeutics files $500M mixed securities shelf

Nov 13, 2025, 7:00 AM EST - 7 months ago

Black Diamond Therapeutics Registration statement: Registration Filing

Nov 12, 2025, 9:00 AM EST - 8 months ago

Black Diamond Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 9:20 AM EST - 8 months ago

Black Diamond Therapeutics Transcript: Stifel 2025 Healthcare Conference

2025-11-06T12:35:52.000Z - 8 months ago

Black Diamond Therapeutics reports Q3 EPS (15c), consensus (23c)

2025-11-06T12:35:40.000Z - 8 months ago

Black Diamond Therapeutics sees cash runway into 4Q27

Nov 6, 2025, 7:30 AM EST - 8 months ago

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 7:00 AM EST - 8 months ago

Black Diamond Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Black Diamond Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 6:00 PM EST - 8 months ago

Black Diamond Therapeutics Slides: Corporate Presentation

2025-10-15T20:36:00.000Z - 9 months ago

Black Diamond Therapeutics resumed with a Buy at Stifel

2025-09-30T16:30:10.000Z - 9 months ago

Black Diamond Therapeutics initiated with a Buy at Freedom Capital

2025-09-04T09:25:07.000Z - 10 months ago

Black Diamond Therapeutics initiated with a Buy at Guggenheim

2025-09-03T20:15:10.000Z - 10 months ago

Black Diamond Therapeutics initiated with a Buy at Guggenheim

2025-08-11T10:21:34.000Z - 11 months ago

Black Diamond price target lowered to $10 from $12 at H.C. Wainwright

2025-08-07T11:42:25.000Z - 11 months ago

Black Diamond Therapeutics reports Q2 EPS (19c), consensus (23c)

2025-08-07T11:42:19.000Z - 11 months ago

Black Diamond Therapeutics sees cash runway into 4Q27

Aug 7, 2025, 7:30 AM EDT - 11 months ago

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Black Diamond Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Black Diamond Therapeutics Quarterly report: Q2 2025

2025-07-01T10:51:03.000Z - 1 year ago

Black Diamond Therapeutics resumed with an Outperform at Raymond James

Jun 4, 2025, 4:20 PM EDT - 1 year ago

Black Diamond Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 12:00 PM EDT - 1 year ago

Black Diamond Therapeutics Slides: Corporate Presentation

May 12, 2025, 4:05 PM EDT - 1 year ago

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 9:30 AM EDT - 1 year ago

Black Diamond Therapeutics Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

Black Diamond Therapeutics Quarterly report: Q1 2025

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 8, 2025, 1:00 PM EDT - 1 year ago

Black Diamond Therapeutics Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 7, 2025, 3:00 PM EDT - 1 year ago

Black Diamond Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 19, 2025, 7:00 AM EDT - 1 year ago

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Mar 6, 2025, 4:01 PM EST - 1 year ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 6, 2025, 9:30 AM EST - 1 year ago

Black Diamond Therapeutics Annual report: Q4 2024

Mar 6, 2025, 9:30 AM EST - 1 year ago

Black Diamond Therapeutics Earnings release: Q4 2024

Dec 4, 2024, 3:00 PM EST - 1 year ago

Black Diamond Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 9:45 AM EST - 1 year ago

Black Diamond Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 7:00 AM EST - 1 year ago

Black Diamond Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Black Diamond Therapeutics Earnings release: Q3 2024

Oct 7, 2024, 4:01 PM EDT - 1 year ago

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Transcript: Study Update

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Press release: Study Update

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Slides: Study Update

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Sep 22, 2024, 10:00 AM EDT - 1 year ago

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Sep 14, 2024, 3:30 AM EDT - 1 year ago

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Aug 6, 2024, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Earnings release: Q2 2024

Jun 1, 2024, 10:00 AM EDT - 2 years ago

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Slides: Corporate Presentation

May 9, 2024, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Earnings release: Q1 2024

Apr 24, 2024, 4:05 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Changes to Board of Directors

Apr 10, 2024, 12:00 PM EDT - 2 years ago

Black Diamond Therapeutics Slides: FY 2024

Apr 7, 2024, 6:00 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Apr 7, 2024, 11:00 AM EDT - 2 years ago

Black Diamond Therapeutics Slides: FY 2024

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Earnings release: Q4 2023

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Annual report: Q4 2023

Mar 5, 2024, 4:30 PM EST - 2 years ago

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

Feb 28, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 4, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

Dec 13, 2023, 7:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Nov 6, 2023, 7:45 AM EST - 2 years ago

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 7:00 AM EST - 2 years ago

Black Diamond Therapeutics Quarterly report: Q3 2023

Nov 6, 2023, 7:00 AM EST - 2 years ago

Black Diamond Therapeutics Earnings release: Q3 2023

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Oct 4, 2023, 12:14 PM EDT - 2 years ago

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Announces CEO Transition

Sep 11, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

Aug 11, 2023, 7:30 AM EDT - 3 years ago

Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Quarterly report: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Earnings release: Q2 2023

Jun 29, 2023, 8:57 PM EDT - 3 years ago

Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock

Jun 28, 2023, 4:23 PM EDT - 3 years ago

Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock

Jun 27, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Jun 13, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 7:30 AM EDT - 3 years ago

Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Quarterly report: Q1 2023

May 9, 2023, 7:00 AM EDT - 3 years ago

Black Diamond Therapeutics Earnings release: Q1 2023

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

Apr 17, 2023, 4:01 PM EDT - 3 years ago

Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Proxy statement: Proxy Filing

Mar 9, 2023, 7:30 AM EST - 3 years ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 9, 2023, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Earnings release: Q4 2022

Mar 9, 2023, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Annual report: Q4 2022

Feb 27, 2023, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

Jan 5, 2023, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 12, 2022, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company

Nov 14, 2022, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Registration statement: Registration Filing

Nov 8, 2022, 8:00 AM EST - 3 years ago

Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Quarterly report: Q3 2022

Nov 8, 2022, 7:00 AM EST - 3 years ago

Black Diamond Therapeutics Earnings release: Q3 2022

Oct 26, 2022, 8:00 AM EDT - 3 years ago

Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

topstockalerts Jun. 25 at 1:29 AM

$BDTX the stock keeps earning a closer look.

0 · Reply

StockScanners Jun. 25 at 1:03 AM

$BDTX keep watch if this holds above 1.80

0 · Reply

Kinghargis Jun. 24 at 11:00 PM

$BDTX some whale just bought a

0 · Reply

Kinghargis Jun. 24 at 8:10 PM

$BDTX 2 dollar calls smell

0 · Reply

topstockalerts Jun. 24 at 8:07 PM

$BDTX the strength here is subtle but persistent.

0 · Reply

Theflash88 Jun. 24 at 7:10 PM

$BDTX Yes

0 · Reply

Kinghargis Jun. 24 at 6:30 PM

$BDTX heard theres news brewing

1 · Reply

BossTrade Jun. 24 at 6:28 PM

$BDTX Usually a run up like this means something about to go down

0 · Reply

kubertradespennies Jun. 24 at 6:15 PM

$BDTX heard the news yet?

0 · Reply

BossTrade Jun. 24 at 5:36 PM

$BDTX I anticipate mild plateau and consolidation before gap up

0 · Reply

PHILMYWALLET Jun. 24 at 5:29 PM

$BDTX at last. +15% today and hopefully +50% tomorrow

0 · Reply

BossTrade Jun. 24 at 5:21 PM

$BDTX Fair market here is around $4.50-$5 They about to get partnered imo If that happens don’t be surprised to see pop to $10

2 · Reply

BossTrade Jun. 24 at 4:06 PM

$BDTX Retraced 69% off the top with low volume takedown. Meaning a major pop coming

0 · Reply

isaacsebring Jun. 24 at 4:03 PM

$BDTX what’s causing the bump today? Not seeing any catalyst out there yet

0 · Reply

BossTrade Jun. 24 at 3:54 PM

$BDTX $DFTX Funded till H2 2028 Nice try diddy

0 · Reply

MaverickFliesSpirit Jun. 24 at 2:03 PM

$DFTX Check what happened to $BDTX after positive results, stock price jump, and then stock offering announcement. I know how this movie ends

1 · Reply

PHILMYWALLET Jun. 22 at 3:25 PM

$BDTX at the current share price, it just about corresponds to their cash on hand. It's like their pipeline has no value ! Get real !

1 · Reply

PHILMYWALLET Jun. 22 at 11:59 AM

$BDTX time for a pop, maybe today or tomorrow

1 · Reply

BossTrade Jun. 18 at 8:54 PM

$BDTX This is completely healthy and a gift. I done this before several times. Patience is all that’s needed

1 · Reply

Jafo333isme Jun. 18 at 6:15 PM

$BDTX this slow bleed is interesting. Stop loss triggered at 1.95. I then bought back about 30% of my position at what I thought was the bottom. Guess not. We need some news or something.

0 · Reply

BossTrade Jun. 18 at 5:39 PM

$BDTX It’s soon. Longer it holds here bigger the pump. Min .5-2x

0 · Reply

PHILMYWALLET Jun. 18 at 4:42 PM

$BDTX time for a rebound, don't you think ?

0 · Reply

1.0.0